

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

<b>Statement of Results status for the study</b>	
<b>Name of Company:</b> GlaxoSmithKline	
<b>Study No:</b> ING114916 (EudraCT#2011-001646-16)	
<b>Product:</b> GSK1349572	
<b>Title:</b> A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescent Patients with Integrase Resistance	
<b>Phase:</b> N/A	
<b>Study Period:</b> June 2012 to September 2016	
<b>Centers:</b> 80	
<b>Number of Subjects:</b> 216	
<b>Publications:</b> NA	
<b>Statement on results availability:</b> This is an Expanded Access Program with limited safety follow-up for regulatory purposes. No formal study report was created for this program and thus no results summary is envisaged.	